J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
The lead drug from Johnson & Johnson’s $6.5 billion buyout of Momenta, now being tested in nearly 10 indications, has cleared a Phase II in a rare blood disorder.
J&J’s therapeutics unit Janssen was sparse on details but said the drug, nipocalimab, met the primary endpoint in the UNITY study. The majority of pregnant patients in the trial experienced a live birth at or after 32 weeks without requiring intrauterine transfusion, or IUT, the Big Pharma said on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
